Form Bio

Executive Summary

Form Bio, founded in 2022 and headquartered in Austin, Texas, is an AI-driven biotechnology company focused on accelerating the development of genetic medicines and genome engineering. The company's proprietary FORMsight AI platform is designed to optimize AAV vectors, enhance CRISPR accuracy, improve protein engineering, and boost manufacturing yields. By leveraging machine learning, Form Bio aims to make genetic medicines safer, smarter, and faster from concept to clinic. The company is currently in the pre-clinical stage and has not disclosed any funding rounds or valuation, indicating an early-stage profile. With a focus on AI-enabled drug discovery and development, Form Bio operates at the intersection of artificial intelligence and genomics, targeting a high-impact area in biotechnology. The company's approach has the potential to significantly reduce the time and cost associated with bringing genetic therapies to market.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Round70% success
• Q3 2026Pharmaceutical Partnership for FORMsight Platform40% success
• Q4 2026Preclinical Data Milestone for Lead Program50% success